<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379209</url>
  </required_header>
  <id_info>
    <org_study_id>RGI-2001-02</org_study_id>
    <nct_id>NCT01379209</nct_id>
  </id_info>
  <brief_title>Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regimmune Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to
      evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients
      undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.

      The study will be separated into two parts; a dose escalation phase to assess safety,
      followed by a large expansion phase to further evaluate the pharmacologic effects of either a
      Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of
      RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include
      higher risk patients and limit the unrelated donor transplants. After safety is established
      in part 1 of the study, the second portion of the study will expand the enrollment criteria
      and allow transplantation by either related or unrelated donors.

      This study will endeavor to identify the dose range at which RGI-2001 has an acceptable
      safety profile, at which biologic activity is observed, and to guide possible dose levels to
      utilize in later phase studies based on biological activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to
      evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients
      undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.

      In Part 1 (Phase 1: Dose Escalation Phase), patients will receive a single intravenous
      administration of RGI-2001 approximately 30 minutes after completion of the transplant
      (either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified)) with the
      dosage based upon the assigned treatment cohort. Eligible patients will be enrolled in five
      to seven centers in the United States. Patients who are undergoing AHSCT will be enrolled in
      a sequential group dose-escalating fashion to determine the safety, tolerability,
      pharmacokinetic profile, and the MTD or MFD of RGI-2001. It is anticipated that up to six
      dose levels will be evaluated in Part 1, with an option for an additional cohort (Cohort 7)
      if the MTD is not reached and pharmacodynamic markers suggest higher doses are warranted.

      In Part 2 (Expansion Phase), one or more doses below the MTD or MFD will be selected based on
      a potential correlation between GvHD and biological activity to further assess safety and
      biologic activity. Approximately 30 patients who are undergoing either allogeneic PBSCs or
      allogenic bone marrow transplantation (unmodified) will be enrolled in Part 2 of the study.

      Patients will be monitored for safety for 29 days after the transplant procedure.

      All patients will be followed for 100 days following transplant procedure for the incidence
      of acute GvHD, according to the Modified Keystone Criteria for grading acute GvHD (Przepiorka
      D, et al)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001</measure>
    <time_frame>By day 29</time_frame>
    <description>The primary outcome measures are:
The incidence and severity of adverse events
The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001, administered as a single intravenous infusion approximately 30 minutes after AHSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects</measure>
    <time_frame>Within 100 days from AHSCT</time_frame>
    <description>Evaluate biomarkers to assess the potential pharmacodynamic effects of RGI-2001 through biomarkers and cytokine assessments. Exploratory biomarkers for efficacy in reducing GvHD include IL-2R, TNFR1, HGF. Cytokines will be evaluated for both safety and for evidence of mechanism of action and include IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, MIG, TNF-α and IFN-γ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RGI-2001</measure>
    <time_frame>Within first 8 days</time_frame>
    <description>Obtain pharmacokinetic parameters such as Cmax, Cmin, Tmax, AUC and half-life of the study drug in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in reducing the intensity of GvHD</measure>
    <time_frame>Within the first 100 days after AHSCT</time_frame>
    <description>The time to onset, peak intensity and course of GvHD after the AHSCT procedure will be monitored according to the Modified Keystone Criteria for Acute Graft-Versus-Host Disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal Dose of RGI-2001</measure>
    <time_frame>Within first 100 days after AHSCT</time_frame>
    <description>Determine optimal doses of RGI-2001 for further evaluation based on pharmacodynamic response and effectiveness in reducing the intensity of GvHD</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Dose escalation cohort 1 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 2 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 3 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 4 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 5 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 6 in part 1 of this study will include 2-6 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 7 in part 1 of this study will include 2-6 patients (optional)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGI-2001</intervention_name>
    <description>A single administration of RGI-2001 on Day 0 post AHSCT.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>KRN-7000</other_name>
    <other_name>RGI-7000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin Inhibitors</intervention_name>
    <description>GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>According to institutional guidelines.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conditioning Regimen</intervention_name>
    <description>Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>According to institutional guidelines</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>Administered for GVHD prophylaxis as per institutional guidelines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mofetil Mycophenolate</intervention_name>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <other_name>Administered for GVHD prophylaxis as per institution guidelines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Administered for GVHD prophylaxis as per institutional guidelines</description>
    <arm_group_label>RGI-2001 + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
    <arm_group_label>RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a hematological malignancy or aplastic anemia (AA) and is undergoing a
             first allogeneic transplant procedure.

          2. Meet one of the following underlying disease criteria:

             a. Acute myelogenous leukemia (AML) i. First or subsequent morphologic remission b.
             Acute lymphoblastic leukemia (ALL) i. First or subsequent morphologic remission c.
             Chronic myelogenous leukemia (CML) i. Chronic phase; or ii. Accelerated phase d.
             Multiple Myeloma (MM) i. Not more than 20% plasma cells in the bone marrow e.
             Myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia (CMML), who
             have received at least one previous induction regimen and have &lt;10% blasts f.
             Myeloproliferative disorder (MPD), including; i. myeloid metaplasia, and ii.
             myelofibrosis g. Non-Hodgkin's Lymphoma (NHL) i. High-risk NHL in first remission; or
             ii. Relapsed or refractory NHL h. Hodgkin's lymphoma (HL) beyond first remission i.
             Aplastic anemia (AA)

          3. Male or female, age ≥18 years of age

          4. Reasonable expectation of survival for at least 3 months, if the transplant procedure
             is successful

          5. Eastern Cooperative Oncology Group (ECOG) status of 0-2 or Karnofsky Performance
             Status (KPS) of &gt; 60

          6. Transplant Donor

               1. Part 1 (Phase 1: Dose Escalation Phase):

                  Unrelated transplant donor with no more than 1 HLA allele or antigen mismatch,
                  defined as loci A, B, C and DR (note: DQ is excluded)

               2. Part 2 (Phase 2a: Expansion Phase):Related or unrelated transplant donor, with no
                  more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note:
                  DQ is excluded).

          7. Source of the allograft

               1. Part 1 (Phase 1: Dose Escalation Phase):Unmodified (non-manipulated) bone marrow,
                  or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the
                  mobilizing agent.

               2. Part 2: (Phase 2a: Expansion Phase) Unmodified (non-manipulated) bone marrow, or
                  mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the
                  mobilizing agent.

          8. Anti-graft-versus-host disease (GvHD) prophylaxis:

             A calcineurin inhibitor [either tacrolimus (FK506) or cyclosporin A)], in combination
             with either methotrexate (MTX), mycophenolate mofetil (MMF) or sirolimus (RAPA) all at
             doses as per the institutional protocols

          9. Adequate hepatic function, with bilirubin not exceeding the upper limit of normal
             (except when attributed to Gilbert's Disease), and AST and ALT of less than 1.5 times
             the upper limit of normal

         10. No clinically significant cardiac conduction disorder on screening ECG

         11. Serum creatinine ≤ 2.0 mg/dL

         12. Female patients of childbearing potential must have a negative serum pregnancy test
             prior to enrollment and must agree to use dual method of contraception for 30 days
             after study drug administration. Approved methods of contraception include, an IUD
             with spermicide, a female condom with spermicide, a diaphragm with spermicide, a
             cervical cap with spermicide, use of a condom with spermicide by sexual partner or a
             sterile sexual partner.

         13. If male, subjects must be sterile or willing to use an approved method of
             contraception from the time of Informed Consent to 30 days after study drug treatment.
             Males must be willing to refrain from sperm donation within 30 days after study drug
             treatment.

         14. No clinically significant acute or chronic medical condition that in the opinion of
             the investigator will interfere with study participation

         15. No clinically significant laboratory abnormalities as determined by the Principal
             Investigator, in consultation with the Sponsor's Medical Monitor

         16. No active infection

         17. Have signed written informed consent before undergoing any study related procedures
             and is willing to comply with all study procedures

        Exclusion Criteria:

          1. Female subjects who are pregnant or lactating

          2. Subjects about to undergo a non-ablative or non-myeloablative transplant

          3. AML or ALL patient who are in relapse (&gt;5% blasts) or who are defined as primary
             refractory

          4. Blast crisis CML

          5. Radiation, chemotherapy, immunotherapy in the previous 3 weeks, unrelated to the
             transplant procedure

          6. Subjects who, in the judgment of the Investigator have not recovered from the effects
             of previous therapy

          7. Subject who is about to undergo cord blood transplantation

          8. Procedures that are intended to deplete regulatory T-cells from donor transplant
             materials

          9. Known or suspected HIV infection

         10. Active hepatitis A, B, or C infection in recipient or donor

         11. Uncontrolled active infection requiring IV antibiotics in recipient or donor

         12. Major surgery within 1 month before Day 0

         13. Participation in an investigational study within 1 month prior to Day 0

         14. Prior treatment with anti-CD3 antibodies

         15. Treatment with anti-CD20 antibodies or anti-thymocyte globulin (ATG) within 3 months
             of the AHSCT procedure (i.e. infusion of transplant material and RGI-2001).

         16. Vaccination within the preceding 2 weeks prior to the planned dose of RGI-2001

         17. Planned vaccination within 2 months after study drug administration

         18. Known history of cardiac dysfunction (e.g. &lt;50% ejection fraction), ischemia,
             conduction abnormalities, or myocardial infarction in the previous six months

         19. Cardiac pacemaker or automatic implantable cardioverter-defibrillator

         20. Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc
             interval &gt;450 ms

         21. Congenital long QT syndrome or family history of long QT syndrome

         22. History of additional risk factors for torsades de pointes (TdP) (e.g., heart failure,
             hypokalemia)

         23. Bundle branch block

         24. Connective tissue/rheumatologic disorders

         25. History of autoimmune disease

         26. History of solid tumor, excluding non-melanoma skin or cervical carcinoma after
             curative resection, within the preceding 5 years

         27. Uncontrolled diabetes

         28. Prior allogeneic hematopoietic stem cell transplantation

         29. Any other prior organ transplant

         30. Psychiatric or addictive disorders that preclude obtaining reliable informed consent

         31. Any other condition that, in the opinion of the investigator, renders the subject
             unsuitable for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Moores Cancer Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>93093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center - The James</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.regimmune.com</url>
    <description>Regimmune Company Website</description>
  </link>
  <link>
    <url>http://www.fhcrc.org</url>
    <description>Fred Hutchinson Cancer Research Center</description>
  </link>
  <link>
    <url>http://med.stanford.edu</url>
    <description>Stanford School of Medicine</description>
  </link>
  <link>
    <url>http://cancer.ucsd.edu/Pages/default.aspx</url>
    <description>UCSD Moores Cancer Center</description>
  </link>
  <link>
    <url>http://cancer.osu.edu/Pages/index.aspx</url>
    <description>OSU The James Comprehensive Cancer Center</description>
  </link>
  <link>
    <url>http://www.dfhcc.harvard.edu/membership/profile/member/1498/0/</url>
    <description>Dana Farber / Mass General Link to Yi-Bin Chen</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <disposition_first_submitted>June 27, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 9, 2019</disposition_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AHSCT</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>Leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>hematological malignancies</keyword>
  <keyword>Graft-versus-host-disease</keyword>
  <keyword>GvHD</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>KRN 7000</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

